Naresh Bumma

2.1k total citations
70 papers, 557 citations indexed

About

Naresh Bumma is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Naresh Bumma has authored 70 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Hematology, 34 papers in Molecular Biology and 21 papers in Oncology. Recurrent topics in Naresh Bumma's work include Multiple Myeloma Research and Treatments (46 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (16 papers) and Protein Degradation and Inhibitors (13 papers). Naresh Bumma is often cited by papers focused on Multiple Myeloma Research and Treatments (46 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (16 papers) and Protein Degradation and Inhibitors (13 papers). Naresh Bumma collaborates with scholars based in United States, Belgium and France. Naresh Bumma's co-authors include Jeffrey A. Zonder, Seongho Kim, Hans C. Lee, Ulka N. Vaishampayan, Srinivas Devarakonda, Abdullah Khan, Ghayathri Jeyakumar, Yvonne A. Efebera, Joseph A. Fontana and Elisabeth I. Heath and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Naresh Bumma

62 papers receiving 545 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Naresh Bumma United States 10 290 266 226 102 79 70 557
Cindy Varga United States 17 519 1.8× 266 1.0× 371 1.6× 170 1.7× 35 0.4× 60 746
Ghee Young Kwon South Korea 7 297 1.0× 125 0.5× 298 1.3× 97 1.0× 17 0.2× 13 495
RA Kyle United States 12 542 1.9× 297 1.1× 540 2.4× 163 1.6× 51 0.6× 17 826
J.J. Sotto France 11 179 0.6× 178 0.7× 148 0.7× 186 1.8× 22 0.3× 17 565
Sosana Delimpasi Greece 12 399 1.4× 364 1.4× 509 2.3× 102 1.0× 36 0.5× 61 649
Susan Bal United States 13 410 1.4× 402 1.5× 503 2.2× 83 0.8× 68 0.9× 80 691
Josefina Galende Spain 13 469 1.6× 329 1.2× 635 2.8× 292 2.9× 35 0.4× 34 893
Atsushi Shinagawa Japan 13 142 0.5× 144 0.5× 208 0.9× 112 1.1× 16 0.2× 39 446
Srinivas K. Tantravahi United States 11 245 0.8× 173 0.7× 199 0.9× 168 1.6× 16 0.2× 70 597
Rafael Martínez Spain 8 168 0.6× 173 0.7× 252 1.1× 123 1.2× 14 0.2× 16 428

Countries citing papers authored by Naresh Bumma

Since Specialization
Citations

This map shows the geographic impact of Naresh Bumma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naresh Bumma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naresh Bumma more than expected).

Fields of papers citing papers by Naresh Bumma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naresh Bumma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naresh Bumma. The network helps show where Naresh Bumma may publish in the future.

Co-authorship network of co-authors of Naresh Bumma

This figure shows the co-authorship network connecting the top 25 collaborators of Naresh Bumma. A scholar is included among the top collaborators of Naresh Bumma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naresh Bumma. Naresh Bumma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hoffman, James E., Naresh Bumma, Joshua Richter, et al.. (2025). Patient-Reported Quality of Life with Linvoseltamab in Triple-Class Exposed Patients with Relapsed/Refractory Multiple Myeloma: 2-year Results from the LINKER-MM1 Phase 1/2 Clinical Trial. Clinical Lymphoma Myeloma & Leukemia. 25. S116–S116. 1 indexed citations
2.
Khan, Abdullah, Glenn S. Kroog, Tito Roccia, et al.. (2025). Radiologic Pseudoprogression Associated With a Positive Response in a Patient With Multiple Myeloma Treated With a BCMA×CD3 Bispecific Antibody: A Case Report. eJHaem. 6(6). e70168–e70168. 1 indexed citations
3.
Boghdadly, Zeinab El, Nidhi Sharma, Naresh Bumma, et al.. (2025). Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab. PubMed. 2(3). 100097–100097. 1 indexed citations
4.
Mansour, Anthony G., Qiuhong Zhao, Francesca Cottini, et al.. (2024). Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. SHILAP Revista de lepidopterología. 5(4). 407–419.
5.
Callander, Natalie S., Rebecca Silbermann, Zhubin Gahvari, et al.. (2024). Combination Regimens in MM Post Autologous Hematopoietic Cell Transplantation (AHCT) to Eliminate MRD Utilizing Iberdomide (COMMANDER): Results of Dose-Finding Component of a Phase 1b/2 Trial. Blood. 144(Supplement 1). 3365–3365. 2 indexed citations
6.
Jagannath, Sundar, Hans C. Lee, Joshua Richter, et al.. (2024). Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7560–7560. 1 indexed citations
7.
Chen, Pei, Naresh Bumma, Abdullah Khan, et al.. (2024). Cytomegalovirus Reactivation in Patients with Multiple Myeloma Treated with Teclistamab: Risk Factors and Clinical Impact. Blood. 144(Supplement 1). 4717–4717. 1 indexed citations
8.
Zonder, Jeffrey A., Hans C. Lee, Joshua Richter, et al.. (2024). P-403 Indirect Comparison of Linvoseltamab Versus Selinexor Plus Dexamethasone for Penta-Exposed Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S267–S267. 1 indexed citations
9.
Broughton, Megan, Nidhi Sharma, Abdullah Khan, et al.. (2024). Evaluation of Characteristics and Outcomes of Patients with Primary and Secondary Plasma Cell Leukemia Treated with Modern Therapies. Blood. 144(Supplement 1). 6980–6980.
10.
Stino, Amro, Naresh Bumma, Rachel M. Smith, et al.. (2023). Lenalidomide in the treatment of anti‐myelin‐associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose. European Journal of Neurology. 31(3). e16164–e16164. 5 indexed citations
11.
Sharma, Nidhi, Qiuhong Zhao, Francesca Cottini, et al.. (2023). Survival outcomes following autologous stem cell transplant with melphalan 140mg/m 2 versus 200mg/m 2 preparative regimens in patients with multiple myeloma. Leukemia & lymphoma. 64(7). 1315–1321.
12.
Zhao, Qiuhong, Nidhi Sharma, Naresh Bumma, et al.. (2023). Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma. Frontiers in Oncology. 13. 1216461–1216461. 1 indexed citations
13.
Zhao, Qiuhong, Naresh Bumma, Rami Kahwash, et al.. (2022). Functional Impairments of Amyloidosis Patients: Physical Therapy Assessment. SHILAP Revista de lepidopterología. 3(3). 414–421. 2 indexed citations
14.
Khan, Abdullah, Muhammad Salman Faisal, Qiuhong Zhao, et al.. (2022). Outcomes After Salvage Autologous Hematopoietic Cell Transplant for Patients With Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience. Clinical Lymphoma Myeloma & Leukemia. 23(3). e182–e189. 3 indexed citations
15.
16.
Shah, Keyur B., Naresh Bumma, Diego Delgado, et al.. (2021). CHARACTERISTICS OF PATIENTS WITH P.V142I MUTATIONS ASSOCIATED WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: INSIGHTS FROM A GENETIC TESTING PROGRAM. Journal of the American College of Cardiology. 77(18). 742–742. 1 indexed citations
17.
Almaani, Salem, Samir V. Parikh, Anjali A. Satoskar, et al.. (2021). Daratumumab in Patients With Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits. Kidney International Reports. 6(8). 2203–2206. 12 indexed citations
18.
Bumma, Naresh, et al.. (2017). Scheduled Outpatient Red Blood Cell Exchange Program Reduces Admission and Complications in Sickle Cell Disease. Blood. 130. 3536–3536. 1 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cindy Varga Breakdown of academic impact, for papers by Ghee Young Kwon Breakdown of academic impact, for papers by RA Kyle Breakdown of academic impact, for papers by J.J. Sotto Breakdown of academic impact, for papers by Sosana Delimpasi Breakdown of academic impact, for papers by Susan Bal Breakdown of academic impact, for papers by Josefina Galende Breakdown of academic impact, for papers by Atsushi Shinagawa Breakdown of academic impact, for papers by Srinivas K. Tantravahi Breakdown of academic impact, for papers by Rafael Martínez
Rankless by CCL
2026